QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 russell-2000-outpaces-sp-500-as-small-caps-anticipate-feds-interest-rate-move

Small-cap stocks are surging ahead of the expected interest rate cut by the Federal Reserve, outperforming their larger-cap cou...

 applied-therapeutics-stock-soars-as-fda-scraps-panel-meeting-for-its-inherited-metabolic-disorder-drug

Applied Therapeutics stock rises as the FDA no longer requires an Advisory Committee meeting, keeping the Priority Review on tr...

Core News & Articles

LUNR: 70% | Intuitive Machines shares are trading higher after the company announced it was awarded a NASA Near Space Network c...

 citigroup-maintains-buy-on-applied-therapeutics-raises-price-target-to-8

Citigroup analyst Yigal Nochomovitz maintains Applied Therapeutics (NASDAQ:APLT) with a Buy and raises the price target from...

 rare-disease-focused-applied-therapeutics-lead-candidate-govorestat-has-blockbuster-potential-analyst-sees-140-stock-upside

William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD...

 william-blair-initiates-coverage-on-applied-therapeutics-with-outperform-rating

William Blair analyst Tim Lugo initiates coverage on Applied Therapeutics (NASDAQ:APLT) with a Outperform rating.

 rbc-capital-reiterates-outperform-on-applied-therapeutics-maintains-12-price-target

RBC Capital analyst Brian Abrahams reiterates Applied Therapeutics (NASDAQ:APLT) with a Outperform and maintains $12 price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION